Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 6/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30694603 | 1.00 | MKNK2 (0.45) | MKNK2PIK3CBEGFRMKNK1CYP1A2 | |
| Oxalic Acid SCHEMBL29680569 | 0.89 | NOTUM (0.41) | MKNK2PIK3CBMKNK1CYP1A2CYP3A4 | |
| SCHEMBL30564554 | 0.80 | PIK3CB (0.33) | MKNK2PIK3CBEGFRAPPMAPT | |
| SCHEMBL13616341 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL18938889 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL22622580 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL2319181 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL27821267 | 0.75 | MKNK2 (0.45) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL24823940 | 0.75 | MKNK2 (0.42) | MKNK2EGFRMKNK1CYP1A2CYP3A4 | |
| SCHEMBL5021603 | 0.75 | MKNK2 (0.42) | MKNK2EGFRMKNK1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360134-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | INST NAT SANTE RECH MED (FR) | 2025-11-27 | — | — | US | claimed |
| EP-4263539-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE TREATMENT OF INFECTIOUS DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2023-10-25 | — | — | EP | claimed |
| WO-2022129376-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2022-06-23 | — | — | WO | claimed |
| CN-102227422-A | Heterocyclic jak kinase inhibitors | ASTRAZENECA AB | 2011-10-26 | — | — | CN | claimed |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | claimed |
| EP-2346859-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | AstraZeneca AB (SE) | 2011-07-27 | — | — | EP | claimed |
| WO-2010038060-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20250360134-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | INST NAT SANTE RECH MED (FR) | 2025-11-27 | — | — | US | disclosed |
| CN-119874707-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114126620-B | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| CN-101506211-A | Kinase antagonists | UNIV CALIFORNIA (US) | 2009-08-12 | — | — | CN | disclosed |
| US-20080107628-A1 | Polymerase inhibitors | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7259154-B2 | Anticancer agents; asthma; rhintis; vision disorders; skin disorders; antiarthritic agents; antiinflammatory agents; antiallergens | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-21 | — | — | US | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | MKNK2 168/4885PIK3CB 729/4885EGFR 349/4885 |
| US-20080107628-A1 | Polymerase inhibitors | POLR2H, POLR2E, POLR1E | MKNK2 2939/4885PIK3CB 1094/4885EGFR 2270/4885 |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | JAK2, JAK1, JAK3 | MKNK2 164/4885PIK3CB 215/4885EGFR 469/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | MKNK2 4219/4885PIK3CB 2015/4885EGFR 1008/4885 |
| US-20250360134-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | SARS1, CCR5, INTS6 | MKNK2 3738/4885PIK3CB 4070/4885EGFR 2949/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | MKNK2 3557/4885PIK3CB 691/4885EGFR 4324/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | MKNK2 2755/4885PIK3CB 3148/4885EGFR 4129/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MKNK2 2354/4885PIK3CB 857/4885EGFR 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.